Vaccine, hepatitis a

Hypersensitivity to hepatitis A-containing vaccine.

Patient with bleeding disorders (e.g. thrombocytopenia), immunosuppression, personal or family history of febrile convulsions, chronic liver disease. Postpone vaccination in patients with acute severe febrile illness. Children. Pregnancy and lactation. Monitoring Parameters Monitor LFT, anaphylaxis and syncope for 15 minutes following administration.

Significant: Syncope, bleeding disorders (e.g. thrombocytopenia). Blood and lymphatic system disorders: Lymphadenopathy. Ear and labyrinth disorders: Otitis media. Eye disorders: Photophobia, conjunctivitis. Gastrointestinal disorders: Nausea, abdominal pain, diarrhoea, dysgeusia, vomiting, constipation, gastroenteritis. General disorders and administration site conditions: Fatigue, fever, malaise, weakness; injection site reactions (e.g. induration, redness, erythema, soreness, swelling). Investigations: Increased creatine phosphokinase. Metabolism and nutrition disorders: Anorexia. Musculoskeletal and connective tissue disorders: Myalgia, arthralgia, hypertonia, back pain, stiffness. Nervous system disorders: Convulsion, dizziness, headache, drowsiness, paraesthesia, migraine, tremor, vertigo, encephalopathy. Psychiatric disorders: Insomnia, irritability, somnolence. Reproductive system and breast disorders: Menstrual disease. Respiratory, thoracic and mediastinal disorders: Pharyngitis, upper respiratory tract infection, asthma, cough, nasal congestion, nasopharyngitis, rhinorrhea, rhinitis. Skin and subcutaneous tissue disorders: Pruritus, rash, urticaria. Vascular disorders: Hot flashes.
Potentially Fatal: Severe hypersensitivity reactions, including anaphylaxis, angioedema, bronchospasm, urticaria).

Decreased efficacy when given with immunosuppressants (e.g. high-dose corticosteroids, cytotoxic drugs). Increased risk of bleeding or haematoma with anticoagulants.

Vaccines, Antisera & Immunologicals